Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4010MR)

This product GTTS-WQ4010MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ4010MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7051MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ11151MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1333
GTTS-WQ14734MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-19A
GTTS-WQ15166MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ7099MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ12046MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ13035MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ7659MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GEN-1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW